Life Sciences

  • March 09, 2026

    Sullivan & Cromwell Advises Agilent On $950M Biocare Buy

    Agilent Technologies Inc. agreed to acquire Biocare Medical, a specialist in clinical and research pathology solutions, in an all-cash transaction valued at $950 million, the company said Monday.

  • March 09, 2026

    JPMorgan Trims But Can't Escape ERISA Drug Costs Suit

    A New York federal judge pared claims Monday against JPMorgan Chase & Co. in a suit from workers who alleged they paid too much for prescription drugs, but opened discovery on allegations that the bank's contract with its pharmacy benefit manager caused transactions prohibited by federal benefits law.

  • March 06, 2026

    Atty Should've Checked Docket, Says Philips CPAP Judge

    An attorney and his client have no one but themselves to blame for the permanent end to a product liability lawsuit over a recalled Philips sleep breathing machine, a Pennsylvania federal judge said on Friday, saying it was on them to monitor the docket.

  • March 06, 2026

    ExThera Exec Hid Patient Deaths To Keep $10M Deal, DOJ Says

    Medical device company ExThera concealed the deaths of two U.S. patients treated with its unapproved blood filtration device at a clinic in Antigua, according to federal prosecutors, with the company agreeing to forfeit nearly $5.7 million and one executive facing up to three years in prison.

  • March 06, 2026

    FDA Vaccine Chief Prasad To Exit Agency For 2nd Time

    Dr. Vinay Prasad, the U.S. Food and Drug Administration's top vaccine regulator, will leave the agency in the coming weeks, FDA Commissioner Marty Makary said Friday.

  • March 06, 2026

    Drugmaker Nektar Faces Suit Over Hair Loss Drug Trial Claims

    Pharmaceutical company Nektar Therapeutics on Friday was hit with a proposed class action accusing it of harming investors by failing to disclose the risks associated with its failure to follow protocol for enrolling participants in an unsuccessful trial for its hair loss treatment.

  • March 06, 2026

    Actelion Pays $65M To Settle Tracleer Antitrust Class Suit

    Actelion Pharmaceuticals Ltd. agreed to pay $65 million to resolve antitrust claims from a certified class accusing it of illegally denying generics companies the samples they need to produce generic versions of its hypertension drug Tracleer, according to a brief in Maryland federal court seeking preliminary approval of the settlement.

  • March 06, 2026

    9th Circ. Mulls Whether Politics Tainted DOJ Trans Care Probe

    A Ninth Circuit panel on Friday grappled with where to draw the line between a legitimate law enforcement investigation and a politically motivated crusade, as the U.S. Department of Justice sought to revive a subpoena against a telehealth provider of gender-affirming medical care.

  • March 06, 2026

    Boston Scientific Investor Sues Over Growth Projections

    A Boston Scientific Corp. investor has filed a proposed class action against the medical device manufacturer and its top brass, claiming they misled shareholders about the sustainability and growth trajectory of the company's electrophysiology segment while failing to disclose competitive pressures and regulatory headwinds.

  • March 06, 2026

    Mass. Judge Told Vax Committee Must Be Fairly Balanced

    A key federal vaccine committee remains subject to statutory requirements that its membership be fairly balanced, a Massachusetts federal judge heard from both U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. and medical organizations challenging his overhaul of the group.

  • March 06, 2026

    Fed. Circ. Won't Reinstate $2M Sepsis-Testing Patent Verdict

    The Federal Circuit on Friday refused to revive the $2 million jury verdict Magnolia Medical Technologies Inc. won in its sepsis-testing patent infringement suit against Kurin Inc., affirming a Delaware federal judge's decision to throw out the verdict after trial.

  • March 06, 2026

    NJ Talc Suit Will Proceed Amid Beasley Allen DQ Appeal

    The New Jersey Supreme Court has declined to stay multicounty litigation over Johnson & Johnson's talc-based baby powder brought by hundreds of women who allege their ovarian cancer was linked to the product, while Beasley Allen appeals its removal as plaintiff's counsel over a firm partner's collaboration with the pharmaceutical giant's former outside counsel.

  • March 06, 2026

    Sanofi Selling Medley Unit To Brazilian Drug Co. For $500M

    French drugmaker Sanofi will sell 100% of Medley, one of Brazil's leading generic drug brands, to Brazilian pharmaceutical conglomerate Grupo EMS, the companies announced Friday. 

  • March 06, 2026

    Express Scripts Ducks RICO Suit Over Acthar Price Hike

    Express Scripts Inc. and its affiliates may have worked with drugmaker Mallinckrodt to hike the price of seizure medication Acthar from $40 to $40,000, but a proposed class action by third-party payors failed to allege the high prices were a result of fraud, a Pennsylvania federal judge ruled.

  • March 06, 2026

    Pa. High Court Snapshot: AG Powers, Gun Parts, CEO Bonus

    The Pennsylvania Supreme Court this month will revisit a ruling on the state attorney general's power over civil suits brought by county-level district attorneys in a case stemming from the Philadelphia and Pittsburgh district attorneys' objections to a $26 billion opioid settlement.

  • March 06, 2026

    Baker McKenzie Guides Servier On $2.5B Oncology Deal

    French pharmaceutical group Servier said Friday that it has agreed to acquire Day One for about $2.5 billion in cash, with legal guidance from Baker McKenzie.

  • March 05, 2026

    Telehealth Co. Swaps In Gordon Rees In Novo's GLP-1 Fight

    A telehealth platform facing allegations from Novo Nordisk that it falsely advertised Ozempic alternatives has picked new counsel in the dispute, withdrawing attorneys from Foley & Lardner LLP and Miller Nash LLP and substituting in two lawyers from Gordon Rees Scully Mansukhani LLP.

  • March 05, 2026

    Fintech Sues Deutsche Bank, Pathward Over Pharma Flags

    A self-described barter-based payment platform sued Deutsche Bank AG and Pathward NA, alleging it was improperly placed on an industry blacklist following the banks' assertions it was "transaction laundering" for companies selling gray-market peptides.

  • March 05, 2026

    Top Patent Officials To Review Sanofi's Double Patenting Win

    U.S. Patent and Trademark Office Director John Squires on Thursday announced he'll be reviewing whether the Patent Trial and Appeal Board properly approved Sanofi's patent application after an obviousness-type double patenting rejection.

  • March 05, 2026

    Pharma Co. Investors Secure Class Cert. Over FDA Obstacles

    A Pennsylvania federal judge has granted certification to a group of Verrica Pharmaceuticals Inc. investors who claim the company defrauded them by hiding obstacles it faced in obtaining approval from the U.S. Food and Drug Administration for its lead product, though she made a slight change to the class definition to avoid what she called a "heads I win, tails you lose strategy."

  • March 05, 2026

    Drugmaker Aquestive Hit With Suit Over FDA Approval Delay

    Pharmaceutical company Aquestive Therapeutics Inc. has been hit with a proposed class action accusing it of harming investors by failing to disclose the likelihood that the U.S. Food and Drug Administration would delay approval of the company's drug application for its allergic reaction treatment.

  • March 05, 2026

    Pfizer Gets OK For $29M SEC Payout From Insider Case

    A New York federal judge on Thursday approved a request from the U.S. Securities and Exchange Commission and Pfizer to have $29 million paid out to a Pfizer subsidiary from the roughly $75.2 million distribution left over from a $602 million insider trading deal.

  • March 05, 2026

    Progenity Investors' $1M Billing Fraud Suit Deal Gets Final OK

    Genetic test distributor Progenity Inc., now known as Biora Therapeutics Inc., has received final approval of a $1 million settlement with investors, resolving claims that it made misleading statements ahead of its June 2020 initial public offering about its practice of overbilling the government.

  • March 05, 2026

    Fed. Circ. Mulls Patents In Penile Implant Trade Secret Win

    A Federal Circuit panel on Thursday grilled both sides in a trade secret dispute over penile implants that resulted in an $18.3 million judgment against defendants, repeatedly questioning attorneys about whether existing patents doomed the trade secrets claimed by International Medical Devices and its founder, Dr. James Elist.

  • March 05, 2026

    9th Circ. Judge 'Frustrated' At DOJ Position On Anti-Trans EOs

    A Ninth Circuit judge said Thursday he's "very frustrated" with the Trump administration's argument that a district court judge acted prematurely by partly blocking executive orders to end funding for gender-affirming care, saying it's "pretty clear" the government was poised to do exactly that.

Expert Analysis

  • Unpacking Key Themes From NY's New Healthcare Strategy

    Author Photo

    New York Gov. Kathy Hochul's 2026 State of the State agenda, read together with the state's fiscal year 2027 executive budget, reflect a clear framework to utilize Medicaid as the state's operating platform for healthcare reform, say attorneys at Sheppard.

  • 5 Different AI Systems Raise Distinct Privilege Issues

    Author Photo

    A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.

  • Opinion

    AI-Assisted Arbitration Needs Safeguards To Ensure Fairness

    Author Photo

    As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, ​​​​​​​clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.